Cytokinetics(CYTK) - 2022 Q4 - Earnings Call Transcript

Good afternoon and welcome ladies and gentlemen to Cytokinetics' Fourth Quarter 2022 Conference Call. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen-only mode. At the company's request, we will open the call for question-and-answer after the presentation. [Operator Instructions] Concurrently, we have plans to substantially expand the development program for aficamten by beginning two new Phase 3 clinical trials in 2023; one, in OHCM with a ...